FCGBP inhibits the development of LSCC and cisplatin resistance through the PIGR/JAK2/STAT3 pathway. Radiol Oncol [Internet]. 2026 Mar. 26 [cited 2026 Sep. 20];60(1):67-75. Available from: https://radioloncol.com/index.php/ro/article/view/4672